ExoDx Prostate (IntelliScore)

Exosome Diagnostics has launched its ExoDx Prostate (IntelliScore), a laboratory-developed test designed to provide clinicians and patients with information to improve the prostate biopsy decision-making process. The test is urine-based, and analyzes samples for three biomarkers on exosomal RNA that are expressed in men with high-grade prostate cancer. It assigns an individual risk score from zero to 100 using an algorithm that combines the relative weighted expression of the three-gene-signature, the company said.